Search

The ulcerative colitis (UC) market across the eight major markets (8MM) is forecast to grow at a compound annual growth rate (CAGR) of 2.8% from $7.2 bn in 2021 to $9.6 bn in 2031, driven by the potential introduction of 11 promising late-stage pipeline products and an increase in the prevalent patient population, according to GlobalData, a leading data and analytics company. GlobalData's report, 'Ulcerative Colitis (UC) Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast to 2031,' reveals that 11 pipeline therapies - Roivant Sciences' RVT-3101, AbbVie's Skyrizi (risankizumab), Eli Lilly's mirikizumab, Janssen's Tremfya, Boehringer Ingelheim's Spesolimab, Reistone Biopharma's ivarmacitinib, Pfizer's ritlecitinib and etrasimod, NImmune Biopharma's omilancor, Abivax's obefazimod and InDex Pharma's cobitolimod - will enter the UC market. Agents with novel routes of administration are anticipated to differentiate such therapies in the UC market. Due to the new rectal route of administration cobitolimod offers, it is anticipated to make an impact in the UC market. Cobitolimod is forecast to launch in the US in 2028 but is expected to face competition from agents such as Janus kinase (JAK) inhibitors ivarmacitinib, ritlecitinib which are also entering the US market in 2028. Although the UC market is projected to grow in the 8MM over the forecast period, limited growth is anticipated in Japan. Mirikizumab and Skyrizi are the only late-stage pipeline products set to launch in Japan. The countries covered in the 8MM ate the US, France, Germany, Italy, Spain, the UK, Japan, and Canada. Original source: Global Data, website: http://www.energy.globaldata.com, Copyright Global Data 2023., market; cobitolimod; enzyme inhibitors; etrasimod; gastrointestinal drugs; ivarmacitinib; mirikizumab; monoclonal antibodies; obefazimod; omilancor; risankizumab; ritlecitinib; Skyrizi; Spesolimab; therapeutic antibodies; Tremfya; AbbVie; Abivax; Boehringer Ingelheim; Eli Lilly; InDex Pharma; Janssen; NImmune [...]